Riskpilot← Back to searchSign inGet full accessBIO-ME AS
ASActiveOrg 917330514Forskningsparken Gaustadalléen 21, 0349 OsloTechnical testing and analysis · NACE 7120Est. 20169 employeesbio-me.com
Revenue 2024
NOK 9,2M
+25% vs 2023
EBITDA margin
-94.8%
+14% vs 2023
Equity ratio
38.4%
Financial strength
Net profit 2024
NOK -9M
+12% vs 2023
| Revenue | NOK 9,2M | +25% |
| EBITDA | NOK -8,7M | +14% |
| Net profit | NOK -9M | +12% |
| Total assets | NOK 8,7M | +6% |
| Equity | NOK 3,3M | +23% |
| Employees | 9 | — |
Legal name
BIO-ME AS
Org number
917330514
Legal form
Aksjeselskap
NACE code
7120 · Technical testing and analysis
Founded
16. juni 2016
Share capital
NOK 507 489
Employees
9 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Utvikling, markedsføring og salg av diagnostiske tester, inkludert programvare og opplæring, og tilstøtende tjenester og ytelser.
Address
Forskningsparken Gaustadalléen 21, 0349 Oslo
Phone
+4797512070
Email
info@bio-me.com
Website
bio-me.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 874 | 3 113 | 5 650 | 7 353 | 9 179 |
| Staff expenses | −4 662 | −0 | −0 | −10 125 | −11 819 |
| EBITDA | −4 657 | −6 593 | −8 694 | −10 130 | −8 701 |
| Depreciation & amort. | −19 | −27 | −25 | −70 | −81 |
| EBIT | −4 676 | −6 620 | −8 718 | −10 201 | −8 782 |
| Net financials | −28 | −243 | 6 | −26 | −184 |
| Profit before tax | −4 705 | −6 863 | −8 713 | −10 226 | −8 966 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −4 705 | −6 863 | −8 713 | −10 226 | −8 966 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 771 | 8 994 | 10 264 | 8 240 | 8 698 |
| Equity | −811 | 4 667 | 4 896 | 2 711 | 3 343 |
| Long-term debt | 3 575 | 2 400 | 2 400 | 0 | 1 750 |
| Short-term debt | 1 007 | 1 928 | 2 969 | 5 529 | 3 605 |
| Total debt | 4 582 | 4 328 | 5 369 | 5 529 | 5 355 |
EBITDA margin
-94.8%
This company
15.8%
Market median
-700% vs market
20202024
Equity ratio
38.4%
This company
38.2%
Market median
+1% vs market
20202024
Return on equity
-268.2%
This company
18.4%
Market median
-1558% vs market
20202024
Net profit margin
-97.7%
This company
8.1%
Market median
-1306% vs market
20202024
Asset turnover
1.06×
This company
1.12×
Market median
+5% vs market
20202024
Debt / equity
1.60×
This company
0.62×
Market median
-158% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
ML Chief Executive Officer | Chief Executive Officer | 2019 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Former (2) | ||
| Board of Directors | 2021 – 2023 | |
| Board of Directors | 2023 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 17.49% | 17.49% | 2024 | |
Ebdus Invest Aps | Company | 8.23% | 8.23% | 2024 |
| Company | 7.31% | 7.31% | 2024 | |
| Company | 6.73% | 6.73% | 2024 | |
| Company | 4.52% | 4.52% | 2024 | |
| Company | 4.41% | 4.41% | 2024 | |
| Individual | 4.14% | 4.14% | 2024 | |
| Company | 4% | 4% | 2024 | |
| Company | 3.63% | 3.63% | 2024 | |
| Company | 3.6% | 3.6% | 2024 | |
| Company | 3.58% | 3.58% | 2024 | |
| Company | 2.55% | 2.55% | 2024 | |
| Individual | 2.44% | 2.44% | 2022 | |
| Individual | 2.25% | 2.25% | 2024 | |
Nescon Aps | Company | 2.24% | 2.24% | 2024 |
| Individual | 2.07% | 2.07% | 2024 | |
Invest4health | Company | 1.93% | 1.93% | 2024 |
| Individual | 1.89% | 1.89% | 2024 | |
| Company | 1.74% | 1.74% | 2024 | |
| Individual | 1.73% | 1.73% | 2024 | |
| Individual | 1.55% | 1.55% | 2024 | |
| Company | 1.12% | 1.12% | 2024 | |
| Individual | 1.04% | 1.04% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIO-ME AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Ludvik Isaksen | Chief Executive Officer | 0 companies |
| Martin Welschof | Board of Directors | 0 companies |
| Sverre Christian Munck | Board of Directors | 0 companies |
| Anne Marie Duus Kristensen | Board of Directors | 0 companies |
| Hilde Furberg | Board of Directors | 0 companies |
| Arne Christian Materna | Board of Directors | 0 companies |
| Carl Christian Gilhuus-Moe | Chairman | 0 companies |